The ophthalmic pharmaceutical market has been less affected than the technology and device market during the ongoing COVID-19 pandemic, but all sectors are down, according to a leading industry expert in an Eyecelerator LiveStream presentation.
“There’s no doubt there’s a difference across the sectors, but I think if you look at the industry as a whole, elective procedures have turned down. Ophthalmology requires devices or med tech use for these procedures, and that’s been seen across the board. There’s definitely been a more significant impact on the devices side,”
Uncategorized